Beyond PD-L1—Identification of Further Potential Therapeutic Targets in Oral Cancer

SIMPLE SUMMARY: Tumor immunotherapy is rapidly evolving and approved for the treatment of advanced OSCC cases. In addition, the currently observed shift in the use of checkpoint inhibitors from palliative to neoadjuvant treatment may improve survival. However, not all patients respond to currently a...

Descripción completa

Detalles Bibliográficos
Autores principales: Weber, Manuel, Lutz, Rainer, Olmos, Manuel, Glajzer, Jacek, Baran, Christoph, Nobis, Christopher-Philipp, Möst, Tobias, Eckstein, Markus, Kesting, Marco, Ries, Jutta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8997752/
https://www.ncbi.nlm.nih.gov/pubmed/35406584
http://dx.doi.org/10.3390/cancers14071812

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8997752/
https://www.ncbi.nlm.nih.gov/pubmed/35406584
http://dx.doi.org/10.3390/cancers14071812

Ejemplares similares